2. Search Result
Search Result
Results for "

dopaminergic

" in MedChemExpress (MCE) Product Catalog:

96

Inhibitors & Agonists

1

Screening Libraries

4

Peptides

13

Natural
Products

17

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W008719
    MPP+ iodide
    10+ Cited Publications

    		 Mitochondrial Metabolism Neurological Disease
    MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .
    MPP+ iodide
  • HY-100705
    DMNB

    6-Nitroveratraldehyde

    		 Others Neurological Disease
    DMNB (6-Nitroveratraldehyde), a precursor, can be used for the synthesis no-carrier-added 6-[ 18F]fluoro-L-DOPA (6-FDOPA). No-Carrier-Added (NCA) 6-[18F]fluoro-L-dopa (6-FDOPA) is being produced routinely for PET investigations of dopaminergic systems .
    DMNB
  • HY-B1693
    Levomepromazine
    1 Publications Verification

    Methotrimeprazine

    		 5-HT Receptor Dopamine Receptor Neurological Disease
    Levomepromazine (Methotrimeprazine) is an orally available neuroleptic agent, which is commonly used to relieve nausea and vomiting in palliative care settings. Levomepromazine has antagonist actions at multiple neurotransmitter receptor sites, including dopaminergic, cholinergic, serotonin and histamine receptors .
    Levomepromazine
  • HY-110080
    Lisuride maleate

    		Dopamine Receptor Neurological Disease
    Lisuride (maleate) is a potent agonist of dopamine with a probably direct action on dopaminergic receptors. Lisuride (maleate) is an ergot derivative. Lisuride (maleate) releases the premenstrual mastalgia without significant side effects .
    Lisuride maleate
  • HY-136390
    ML417

    		Dopamine Receptor Neurological Disease
    ML417 is a selective and brain penetrant D3 dopamine receptor (D3R) agonist, with an EC50 of 38 nM. ML417 potently promotes D3R-mediated β-arrestin translocation, G protein mediated signaling, and pERK phosphorylation with minimal effects on other GPCR-mediated signaling. ML417 exhibits neuroprotection against toxin-induced neurodegeneration of dopaminergic neurons .
    ML417
  • HY-19005
    GYKI-32887

    		Dopamine Receptor Neurological Disease
    GYKI-32887 is a dopaminergic agonist that can reduce the motor activity levels in rats .
    GYKI-32887
  • HY-116507
    AZD0328

    		nAChR Neurological Disease
    AZD0328 is a selective α7 nAChR partial agonist. AZD0328 selectively enhances midbrain dopaminergic neuronal activity and enhances cortical dopamine levels in rats. AZD0328 improves cognitive performance .
    AZD0328
  • HY-120016
    RU 43044

    		Glucocorticoid Receptor Neurological Disease
    RU 43044 is a glucocorticoid receptor antagonist. RU 43044 shows an antidepressant-like effect, probably via an inhibition of enhanced prefrontal dopaminergic neurotransmission in these mouse models .
    RU 43044
  • HY-W709760
    7-hydroxychlorpromazine

    		Endogenous Metabolite Neurological Disease
    7-Hydroxychlorpromazine is an active metabolite of Chlorpromazine (HY-12708). 7-Hydroxychlorpromazine reverses Amphetamine-induced depression of regional compact dopaminergic neurons .
    7-hydroxychlorpromazine
  • HY-B1693R
    Levomepromazine (Standard)

    		5-HT Receptor Dopamine Receptor Neurological Disease
    Levomepromazine (Standard) is the analytical standard of Levomepromazine. This product is intended for research and analytical applications. Levomepromazine (Methotrimeprazine) is an orally available neuroleptic agent, which is commonly used to relieve nausea and vomiting in palliative care settings. Levomepromazine has antagonist actions at multiple neurotransmitter receptor sites, including dopaminergic, cholinergic, serotonin and histamine receptors .
    Levomepromazine (Standard)
  • HY-139308
    T0467
    1 Publications Verification

    		 PINK1/Parkin Mitochondrial Metabolism Neurological Disease
    T0467 activates parkin mitochondrial translocation in a PINK1-dependent manner in vitro. T0467 do not induce mitochondrial accumulation of PINK1in dopaminergic neurons. T0467 is a potential compound for PINK1-Parkin signaling activation, and can be used for parkinson's disease and related disorders research .
    T0467
  • HY-B1124
    Fipexide
    1 Publications Verification

    		 Adenylate Cyclase Dopamine Transporter Neurological Disease
    Fipexide, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide reduces striatal adenylate cyclase activity. Fipexide has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide is used for senile dementia research. Fipexide acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection .
    Fipexide
  • HY-B1124A
    Fipexide hydrochloride
    1 Publications Verification

    		 Adenylate Cyclase Dopamine Transporter Neurological Disease
    Fipexide hydrochloride, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide hydrochloride reduces striatal adenylate cyclase activity. Fipexide hydrochloride has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide hydrochloride is used for senile dementia research. Fipexide hydrochloride acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection .
    Fipexide hydrochloride
  • HY-160426
    Gcase activator 3

    		Glucosidase Neurological Disease
    Gcase activator 3 (compound 9Q) is a glucosidase (Glucosidase, GCase) activator that can partially stabilize GCase and increase its activity. Gcase activator 3 reduces mutant GCase protein misfolding and degradation in fibroblasts and dopaminergic midbrain neurons. Gcase activator 3 can be used in the study of Parkinson's disease (PD) and related synucleinopathies .
    Gcase activator 3
  • HY-W152604
    Cyclo(glycyl-L-leucyl)

    Cyclo(leu-gly)

    		 Dopamine Receptor Neurological Disease
    Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .
    Cyclo(glycyl-L-leucyl)
  • HY-119857
    AGK7

    SIRT2 Inhibitor,Inactive Control

    		 Sirtuin Neurological Disease
    AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease .
    AGK7
  • HY-B1124R
    Fipexide (Standard)

    		Adenylate Cyclase Dopamine Transporter Neurological Disease
    Fipexide (Standard) is the analytical standard of Fipexide. This product is intended for research and analytical applications. Fipexide, a parachloro-phenossiacetic acid derivative, is an orally active nootropic agent. Fipexide reduces striatal adenylate cyclase activity. Fipexide has positive effect on cognitive performance by dopaminergic neurotransmission. Fipexide is used for senile dementia research. Fipexide acts as a chemical inducer in callus formation, shoot regeneration and Agrobacterium infection .
    Fipexide (Standard)
  • HY-152171
    GZ-11608

    		Monoamine Transporter Neurological Disease
    GZ-11608 is a potent and selective vesicular monoamine transporter-2 (VMAT2) inhibitor with high affinity (Ki = 25 nM). GZ-11608 decreases methamphetamine-induced dopamine release from isolated synaptic vesicles from brain dopaminergic neurons. GZ-11608 exhibits rapid brain penetration and without neurotoxicity. GZ-11608 can be used for the research of methamphetamine use disorder .
    GZ-11608
  • HY-158732
    MAO-B-IN-33

    		Monoamine Oxidase Inflammation/Immunology
    MAO-B-IN-33 (compound C3) is a potent, reversible and selective monoamine oxidase-B (MAO-B) inhibitor with an IC50 of 0.021 μM and 26.805 μM for MAO-B and MAO-A, respectively. The selectivity of MAO-B-IN-33 is attributed to the steric clash arising from the residue differences between Phe208 (MAO-A) and Ile199 (MAO-B). MAO-B-IN-33 inhibits cerebral MAO-B activity and alleviates MPTP (HY-15608)-induced dopaminergic neuronal loss in the mouse. MAO-B-IN-33 has the potential for Parkinson's disease research .
    MAO-B-IN-33
  • HY-W001601
    Budipine

    		iGluR Neurological Disease
    Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .
    Budipine
  • HY-W001601A
    Budipine hydrochloride

    		iGluR Neurological Disease
    Budipine hydrochloride is an anti-parkinson agent. Budipine hydrochloride also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine hydrochloride also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine hydrochloride can be used for the research of CNS disorders include Parkinson disease .
    Budipine hydrochloride
  • HY-W001601R
    Budipine (Standard)

    		iGluR Neurological Disease
    Budipine (Standard) is the analytical standard of Budipine. This product is intended for research and analytical applications. Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease .
    Budipine (Standard)
  • HY-N0303
    Idebenone
    5+ Cited Publications

    		 Mitochondrial Metabolism Apoptosis Neurological Disease
    Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.
    Idebenone
  • HY-160997
    Prosulpride

    GRI 1665

    		 Dopamine Receptor Neurological Disease
    Prosulpride (GRI 1665), a neuroleptics, can block selectively dopaminergic receptor .
    Prosulpride
  • HY-147319
    RTI-7470-44

    		Others Neurological Disease
    RTI-7470-44 is a potent, selective and blood-brain barrier (BBB) penetrant human trace amine-associated receptor subtype 1 (hTAAR1) antagonist with an IC50 value of 8.4 nM and a Ki value of 0.3 nM. RTI-7470-44 has moderate metabolic stability, and a favorable preliminary off-target profile. RTI-7470-44 can increase the spontaneous firing rate of mouse ventral tegmental area (VTA) dopaminergic neurons. RTI-7470-44 can be used for researching schizophrenia, agent addiction, and Parkinson’s disease (PD) .
    RTI-7470-44
  • HY-N0303R
    Idebenone (Standard)

    		Mitochondrial Metabolism Apoptosis Neurological Disease
    Idebenone (Standard) is the analytical standard of Idebenone. This product is intended for research and analytical applications. Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.
    Idebenone (Standard)
  • HY-W016498
    Paraxanthine
    2 Publications Verification

    		 Drug Metabolite Endogenous Metabolite Neurological Disease
    Paraxanthine, a caffeine metabolite, provides protection against Dopaminergic cell death via stimulation of Ryanodine Receptor Channels.
    Paraxanthine
  • HY-B1225
    Promazine hydrochloride

    Romtiazin hydrochloride; Ampazine hydrochloride; Berophen hydrochloride

    		 Dopamine Receptor Neurological Disease
    Promazine (Romtiazin) hydrochloride is an antipsychotic and a dopamine receptor D2 antagonist. Promazine hydrochloride inhibits dopaminergic neurotransmission .
    Promazine hydrochloride
  • HY-B1225A
    Promazine

    Romtiazin; Ampazine; Berophen

    		 Dopamine Receptor Neurological Disease
    Promazine (Romtiazin) is an antipsychotic and a dopamine receptor D2 antagonist. Promazine inhibits dopaminergic neurotransmission .
    Promazine
  • HY-113356
    m-Tyramine

    		Endogenous Metabolite Neurological Disease
    m-Tyramine is an endogenous trace amine neuromodulator. m-Tyramine has effects on the adrenergic and dopaminergic receptor [1, 2].
    m-Tyramine
  • HY-128975
    m-Tyramine hydrobromide

    		Endogenous Metabolite Neurological Disease
    m-Tyramine hydrobromide is an endogenous trace amine neuromodulator. m-Tyramine hydrobromide has effects on the adrenergic and dopaminergic receptor [1, 2].
    m-Tyramine hydrobromide
  • HY-W016498S
    Paraxanthine-d6

    		Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease
    Paraxanthine-d6 is the deuterium labeled Paraxanthine. Paraxanthine, a caffeine metabolite, provides protection against Dopaminergic cell death via stimulation of Ryanodine Receptor Channels.
    Paraxanthine-d6
  • HY-W008719S
    MPP+-d3(iodide)

    		Mitochondrial Metabolism Neurological Disease
    MPP+-d3 (iodide) is deuterium labeled MPP+ (iodide). MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT)[1][2].
    MPP+-d3(iodide)
  • HY-W016498R
    Paraxanthine (Standard)

    		Drug Metabolite Endogenous Metabolite Neurological Disease
    Paraxanthine (Standard) is the analytical standard of Paraxanthine. This product is intended for research and analytical applications. Paraxanthine, a caffeine metabolite, provides protection against Dopaminergic cell death via stimulation of Ryanodine Receptor Channels.
    Paraxanthine (Standard)
  • HY-125602
    MNI-444

    		Adenosine Receptor Neurological Disease
    MNI-444 is a BBB-penetrable ligand of adenosine 2A receptor (A2AR). A2AR is a potential non-dopaminergic target for the research of Parkinson’s disease .
    MNI-444
  • HY-116578
    Metopimazine

    EXP999; RP9965

    		 Others Inflammation/Immunology
    Metopimazine (EXP999) is a phenothiazine derivative used to prevent emesis during chemotherapy. Metopimazine belongs to the anti-dopaminergic anti-emetics (ADA) class. Metopimazine can be used for the research of gastroenteritis (GE) .
    Metopimazine
  • HY-155206
    (+)-OSU6162

    		5-HT Receptor Neurological Disease
    (+)-OSU6162 is an stabilizer on dopaminergic and serotonergic brain signaling. (+)-OSU6162 is a partial agonist of 5-HT2A receptor. (+)-OSU6162 can be used for neurological research .
    (+)-OSU6162
  • HY-124876
    SynuClean-D

    SC-D

    		 α-synuclein Neurological Disease
    SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .
    SynuClean-D
  • HY-19489S1
    (Rac)-Levomepromazine-d3 hydrochloride

    (Rac)-Methotrimeprazine-d3 hydrochloride

    		 Isotope-Labeled Compounds Dopamine Receptor Histamine Receptor Neurological Disease
    (Rac)-Levomepromazine-d3 (hydrochloride) is a labelled racemic Methotrimeprazine, which is a phenothiazine which has antagonist actions at multiple neurotransmitter receptor sites, including dopaminergic, cholinergic, serotonin and histamine receptors[1][2].
    (Rac)-Levomepromazine-d3 hydrochloride
  • HY-123506
    Fenlean

    		Src Neurological Disease Inflammation/Immunology
    Fenlean, a natural squamosamide derivative, is a Src tyrosine kinase inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson's disease models .
    Fenlean
  • HY-B0282
    Acetylcholine chloride
    10+ Cited Publications

    ACh chloride

    		 nAChR Calcium Channel Endogenous Metabolite Neurological Disease Cancer
    Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs) . Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro .
    Acetylcholine chloride
  • HY-N0109
    Salidroside
    Maximum Cited Publications
    24 Publications Verification

    Rhodioloside

    		 PINK1/Parkin mTOR Apoptosis Prolyl Endopeptidase (PREP) Cancer
    Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.
    Salidroside
  • HY-P6437
    Drp1 peptide inhibitor P110

    		Dynamin Cardiovascular Disease Neurological Disease
    Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .
    Drp1 peptide inhibitor P110
  • HY-W016498S1
    Paraxanthine-13C4,15N3

    		Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease
    Paraxanthine- 13C4, 15N3 is the 13C-labeled and 15N-labeled Paraxanthine. Paraxanthine, a caffeine metabolite, provides protection against Dopaminergic cell death via stimulation of Ryanodine Receptor Channels.
    Paraxanthine-13C4,15N3
  • HY-U00280
    Potassium Channel Activator 1

    		Others Neurological Disease
    Potassium Channel Activator 1 is an agent for treating, one or more disorders or conditions wherein the dopaminergic system is disrupted, such as one or more disorders or conditions independently selected from the group consisting of: schizophrenia and other psychotic states; mood disorders ADHD; aggression; movement disorders.
    Potassium Channel Activator 1
  • HY-N12657
    Retinestatin

    		Others Neurological Disease
    Retinestatin, a new polyol polyketide, can protect SH-SY5Y dopaminergic cells from MPP + (HY-W008719)-induced cytotoxicity. Retinestatin shows neuroprotective effects in an in vitro model of Parkinson’s disease .
    Retinestatin
  • HY-14608S
    L-Glutamic acid-13C

    		Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease
    L-Glutamic acid- 13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
    L-Glutamic acid-13C
  • HY-14608S7
    L-Glutamic acid-d5

    		Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease
    L-Glutamic acid-d5 is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
    L-Glutamic acid-d5
  • HY-14608S8
    L-Glutamic acid-d3

    		Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease
    L-Glutamic acid-d3 is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
    L-Glutamic acid-d3
  • HY-14608S5
    L-Glutamic acid-13C5

    		Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease
    L-Glutamic acid- 13C5 is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
    L-Glutamic acid-13C5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: